|LETTER TO THE EDITOR
|Year : 2015 | Volume
| Issue : 7 | Page : 625
Query to the author of retinoblastoma: Achieving new standards with methods of chemotherapy
Sanjiv Kumar Gupta1, Ajai Kumar2, Arun Sharma1, Vishal Katiyar1, Siddharth Agrawal1
1 Department of Ophthalmology, King George's Medical University, Lucknow, Uttar Pradesh, India
2 Jankalyan Eye Hospital, Lucknow, Uttar Pradesh, India
|Date of Web Publication||12-Oct-2015|
Dr. Sanjiv Kumar Gupta
Department of Ophthalmology, King George's Medical University, Lucknow, Uttar Pradesh
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Gupta SK, Kumar A, Sharma A, Katiyar V, Agrawal S. Query to the author of retinoblastoma: Achieving new standards with methods of chemotherapy. Indian J Ophthalmol 2015;63:625
We have read the symposium article titled "Retinoblastoma: Achieving new standards with methods of chemotherapy" by Kaliki and Shields  with great interest and appreciate their effort to summate the present status of chemotherapy for retinoblastoma.
We noticed that the Figure 2 depicted in the article on page number 105 of the journal, claims that the systemic chemotherapy reduces the size of orbital retinoblastoma as per the attached legend "Treatment of the orbital retinoblastoma with intravenous chemotherapy (a) Orbital retinoblastoma of the left eye confirmed on (b) computed tomography scan of the orbit. (c and d) Nine cycles of high-dose chemotherapy resulted in phthisis bulbi facilitating enucleation. No residual tumor was noted on histopathology. The patient subsequently underwent left orbit external beam radiotherapy and further three cycles of high-dose chemotherapy."
The figure depicts the change in retinoblastoma tumor of single patient over a period of time after systemic chemotherapy. However, it is obvious that the images depicted are of two separate patients and the one labeled (a) with advanced tumor is of a patient with older age, darker iris, and a mole on the left slope of the nasal bridge. The image (c) of Figure 2 is a different patient with lighter iris and no mole at the mentioned site.
We would like to thank the authors for explaining the anomaly.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Kaliki S, Shields CL. Retinoblastoma: Achieving new standards with methods of chemotherapy. Indian J Ophthalmol 2015;63:103-9.